Eversana, Cryoport partner on regenerative medicine supply chain
Biopharmaceutical logistics services provider Cryoport announced a strategic alliance under which Eversana will gain access to its full offering of logistics solutions’.
Specifically, the alliance will see Eversana adopt Cryoport’s express shippers, Cryoportal logistics management platform, SmartPak II condition monitoring system, and logistics management.
The partners expect this alliance to enable an effective supply chain solution for therapeutic advancements of Eversana’s clients and support the development of regenerative medicines, including CAR T-cell and gene therapies.
Jim Lang, CEO of Eversana said in a statement:“The promise of regenerative medicine requires an innovative look at the complete product life cycle from market access planning through efficient distribution and best-in-class patient support.”
"[Cryoport’s] temperature-controlled logistics solutions are currently used by almost all of the leading biopharma companies,” Lang noted, adding that the alliance will drive revenue growth for both companies and provide value to clients.
Jerrell Shelton, CEO of Cryoport, said Eversana is ‘building a powerhouse,’ serving over 500 life sciences companies in over 100 therapeutics areas, and commented that this partnership answers the demand for temperature-controlled supply chain services.
According to Shelton, “The regenerative therapy market is in its infancy with support requirements evolving and this alliance is designed to capture the vast opportunities at the "head of the stream.”
